Thymosin Alpha-1

Endogenous thymic peptide - immune modulator, not stimulant; approved as Zadaxin in 30+ countries.

ClinicalEndogenousInjectableImmune

Key facts

Common routesSubcutaneous

Half-life~2 hours

Typical range450 mcg - 1.6 mg, 2-3x/week

Summary

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland. As Zadaxin, it's approved in 30+ countries - for hepatitis B, hepatitis C, and as an adjuvant in oncology and vaccines. The mode of action is modulatory rather than just stimulatory: Tα1 drives T-cell maturation, activates TLR9 on dendritic cells, and raises MHC-I expression.

Community use focuses on age-related immune decline, maintenance during chronic viral loads, and enhancing vaccine response. The evidence base is unusually strong for a peptide in this category, and clinically Tα1 is considered one of the best-validated and best-tolerated immune peptides available.

Mechanism notes

TLR9 activation

Activates Toll-like receptor 9 on dendritic cells and other immune cells. Triggers the MyD88-dependent cascade that upregulates type I interferons (α/β) - the first line of innate antiviral defense.

T-cell maturation

Drives differentiation of immature thymocytes into functional CD4+ and CD8+ T-cells. Particularly relevant with age-related thymic involution, where the T-cell starting pool shrinks.

MHC-I upregulation

Increases MHC-I expression on infected cells, making them more visible to cytotoxic T-cells (CD8+). Important for recognizing cells “hiding” viruses or mutated proteins.

Dosing patterns

Maintenance protocol (immune support)

450 mcg - 1.6 mg subcutaneous, 2-3× per week. Mirrors pulsatile thymic release and maintains T-cell surveillance without over-stimulating the system. A cycle (e.g. 3 months on / 1 month off) is common, though clinical data show no neutralizing antibodies even with years of continuous use.

Acute / antiviral protocol

1.6 mg daily for 7-14 days during active infection, or dosed around a vaccine (1.6 mg on vaccine day, optionally 3 days prior). This is the clinical pattern when rapid immune response is needed.

Evidence snapshot

Phase 3 data supports Zadaxin approval in 30+ countries for HBV, HCV, and melanoma adjuvant therapy. Beyond that there's broad clinical literature on enhancing vaccine response in immunocompromised patients. Extrapolation to healthy users is plausible but not supported by large RCTs in that population.

Approved uses (Zadaxin)

HBV, HCV, and melanoma adjuvant in 30+ countries; no FDA approval but previously held FDA Orphan Drug designation. Safety data stretches across decades of clinical use.

Off-label and community use

Immune support in chronic infections, vaccine response enhancement, supportive therapy during chemotherapy-induced immunosuppression.

Safety considerations

Excellent safety profile across decades of clinical use. Unlike interferons or interleukin-2, Tα1 doesn't cause the typical “flu-like” symptoms or severe cytopenias. The most common reaction is mild local injection-site irritation. The practically relevant risk is context-dependent: transplant patients are contraindicated.

Key cautions

Absolute contraindication for organ transplant recipients - rejection risk from boosted T-cell activity
Start low (50-100 mcg) if you have an autoimmune condition (Hashimoto's, Lupus, RA) to gauge response
Corticosteroids and potent immunosuppressants can blunt Tα1's immune-modulating effect